Inceptive vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Inceptive designs synthetic RNA molecules for therapeutic applications using deep learning and high-throughput experiments; targets mRNA medicines, RNA-based vaccines, and gene regulation; raised $100M Series A led by Andreessen Horowitz;
About
Inceptive is a Berlin and San Francisco-based biotechnology company founded in 2021 by Jakob Uszkoreit (former senior scientist at Google Brain and co-inventor of the Transformer architecture), Rhiju Das (Stanford RNA biophysicist), and other co-founders. The company is applying deep learning to the problem of RNA design — predicting and engineering synthetic RNA sequences that fold into specific structures and perform specific biological functions, such as encoding therapeutic proteins (mRNA medicines), silencing disease genes (siRNA, antisense), or regulating cellular behavior through aptamers and riboswitches.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.